Q4 2019 13F Holders as of 31 Dec 2019
-
Type / Class
-
Equity / Common Stock, $0.0001 par value
-
Shares outstanding
-
125,684,656
-
Total 13F shares
-
43,885,493
-
Share change
-
+2,565,781
-
Total reported value
-
$1,343,772,430
-
Put/Call ratio
-
92%
-
Price per share
-
$30.62
-
Number of holders
-
132
-
Value change
-
+$85,692,286
-
Number of buys
-
73
-
Number of sells
-
60
Institutional Holders of Apellis Pharmaceuticals, Inc. - Common Stock, $0.0001 par value (APLS) as of Q4 2019
As of 31 Dec 2019,
Apellis Pharmaceuticals, Inc. - Common Stock, $0.0001 par value (APLS) was held by
132 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
43,885,493 shares.
The largest 10 holders included
BlackRock Inc., HILLHOUSE CAPITAL ADVISORS, LTD., WELLINGTON MANAGEMENT GROUP LLP, Cormorant Asset Management, LP, VANGUARD GROUP INC, STATE STREET CORP, VICTORY CAPITAL MANAGEMENT INC, FIL Ltd, BARCLAYS PLC, and JENNISON ASSOCIATES LLC.
This page lists
132
institutional shareholders reporting positions in this security
for the Q4 2019 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.